Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.03 CAD
Change Today +0.005 / 20.00%
Volume 50.0K
KNE On Other Exchanges
As of 1:37 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

kane biotech inc (KNE) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - C$0.07
52 Week Low
11/24/14 - C$0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KANE BIOTECH INC (KNE)

Related News

No related news articles were found.

kane biotech inc (KNE) Related Businessweek News

No Related Businessweek News Found

kane biotech inc (KNE) Details

Kane Biotech Inc., a biotechnology company, develops and commercializes products that prevent and remove microbial biofilms. It develops wound care solutions under the DispersinB and AloSera trademarks; medical device coatings under the Aledex trademark; and oral care solutions under the StrixNB and bluestem trademarks. The company also offers its products under the coactive+ and Kane trademarks. In addition, it offers KBI Antibacterial Disinfectant. The company was founded in 2001 and is based in Winnipeg, Canada.

Founded in 2001

kane biotech inc (KNE) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

kane biotech inc (KNE) Key Developments

Kane Biotech Inc. Announces Extension of Three Year Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research (USAISR)

Kane Biotech Inc. announced three year Cooperative Research and Development Agreement (CRADA) extension has been signed with the U.S. Army Institute of Surgical Research (USAISR) in Fort Sam Houston, Texas. The primary objective of this collaboration on ‘Treatments to Prevent Biofilm Formation for Promoting Wound Healing’ is to develop an antibiofilm-antimicrobial wound gel formulation and test the said gel formulation to address the needs of the United States Army Dental and Trauma Research Detachment's (USADTRD) programs and that can be readily translated into clinical testing for improving the outcomes of wounded casualties. The mission of USADTRD is to provide military relevant research and solutions to treat and rehabilitate craniomaxillofacial trauma and prevent infectious disease. The USADTRD's Biofilm Impaired Wound Healing program focuses on providing algorithms to understand biofilm pathophysiology and test agents useful to treat not only dental biofilm (plaque) and combat wounds-associated biofilm infections, but also to provide antimicrobials for the control of dental plaque-associated oral infections.

Kane Biotech Signs on Joint Development Agreement with an Global Animal Health Company

Kane Biotech signed a joint development agreement with an undisclosed global animal health company. Initial revenue from the agreement is USD 100,000, which will be included in the firm's second quarter financial statements. Terms of the agreement are confidential.

Kane Biotech Inc. Announces Management Changes

Kane Biotech Inc. announced Gord Froehlich will retire as Chief Executive Officer. The Board has appointed Mark Ahrens-Townsend as President and CEO to replace Froehlich, effective May 11, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KNE:CN C$0.03 CAD +0.005

KNE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KNE.
View Industry Companies

Industry Analysis


Industry Average

Valuation KNE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.1x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KANE BIOTECH INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at